Emmaus Life Sciences, Inc. (EMMA)

OTCMKTS: EMMA · Delayed Price · USD
0.320
+0.074 (30.08%)
Jun 2, 2023, 10:26 AM EDT - Market closed
Market Cap 14.37M
Revenue (ttm) 21.91M
Net Income (ttm) -12.61M
Shares Out 49.56M
EPS (ttm) -0.47
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 500
Open 0.320
Previous Close 0.246
Day's Range 0.320 - 0.320
52-Week Range 0.071 - 0.600
Beta 1.92
Analysts n/a
Price Target n/a
Earnings Date Nov 12, 2019

About EMMA

Emmaus Life Sciences, Inc., a commercial-stage biopharmaceutical company, discovers, develops, markets, and sells treatments and therapies primarily for rare and orphan diseases in the United States and internationally. The company's lead candidate is Endari, an L-glutamine oral powder to reduce the acute complications of sickle cell disease in adult and pediatric patients five years of age and older. It has a collaboration agreement with Kainos Medicine, Inc. for the preclinical development of Kainos' patented IRAK4 inhibitor (KM10544) as an a... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2000
Employees 54
Stock Exchange OTCMKTS
Ticker Symbol EMMA
Full Company Profile

Financial Performance

In 2022, EMMA's revenue was $18.39 million, a decrease of -10.77% compared to the previous year's $20.61 million. Losses were -$10.69 million, -32.99% less than in 2021.

Financial Statements

News

Emmaus Life Sciences Receives Endari® Marketing Authorization from the Bahrain NHRA

TORRANCE, Calif. , May 31, 2023 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX: EMMA), a leader in sickle cell disease treatment, announced today that it has received a Medicine Registration Certif...

2 days ago - PRNewsWire

Emmaus Life Sciences Reports Q1 2023 Financial Results and Provides Business Update

TORRANCE, Calif. , May 15, 2023 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today reporte...

2 weeks ago - PRNewsWire

Emmaus Life Sciences Provides Interim Shipment Data

TORRANCE, Calif. , April 3, 2023 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX: EMMA), a leader in sickle ell disease treatment, announced today preliminary results for the 3 months ended March 31...

2 months ago - PRNewsWire
}

Emmaus Life Sciences Reports 2022 Financial Results and Provides Business Update

TORRANCE, Calif. , March 31, 2023 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today repor...

2 months ago - PRNewsWire

Dr. Niihara Meets with Local Indian Governor

Cites Large, Unserved Needs of Sickle Cell Disease Patients   TORRANCE, Calif. , Dec. 20, 2022 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX: EMMA), announced today that Dr. Yutaka Niihara, Chairm...

5 months ago - PRNewsWire

Dr. Niihara Feted by Indian Government in Recognition of the Development of Endari®

Celebrity Event Hosted in Mumbai, India   TORRANCE, Calif., Dec. 19, 2022 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX: EMMA), announced today that Dr. Yutaka Niihara, Chairman and Chief Executiv...

5 months ago - PRNewsWire

Endari® Receives Kuwaiti Marketing Authorization

Kuwait is Third Gulf Cooperation Council Country to Approve Endari ® TORRANCE Calif. , Dec. 7, 2022 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX: EMMA), a leader in sickle cell disease treatment,...

6 months ago - PRNewsWire

Emmaus Life Sciences Receives Endari® Marketing Authorization from the Qatar Ministry of Public Health

Company Receives First Major Purchase Order in Saudi Arabia TORRANCE, Calif. , Nov. 17, 2022 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQB: EMMA), a leader in sickle cell disease treatment, announ...

7 months ago - PRNewsWire
}

Emmaus Life Sciences Reports Q3 2022 Financial Results and Provides Business Update

TORRANCE, Calif. , Nov. 14, 2022 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today report...

7 months ago - PRNewsWire

Emmaus Life Sciences Announces Collaboration with Kier (Junior) Spates to Share Personal Experience with Sickle Cell Disease and Endari®

Nationally Syndicated Radio Programming Will Educate and Support SCD Patients TORRANCE, Calif. , Sept. 28, 2022 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX: EMMA) a commercial-stage biopharmaceu...

8 months ago - PRNewsWire

Emmaus Life Sciences Reports Q2 2022 Financial Results and Provides Business Update

TORRANCE, Calif. , Aug. 15, 2022 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today report...

10 months ago - PRNewsWire

Emmaus Life Sciences Announces Engagement of Strategic Business Relations and Professional Services Advisor

Acorn Management Partners Will Develop and Implement a Market Awareness Program Targeting Financial Professionals TORRANCE, Calif. , July 12, 2022 /PRNewswire/ -- Emmaus Life Sciences, Inc.  (OTCQX: E...

11 months ago - PRNewsWire

Emmaus Life Sciences Reports Q1 2022 Financial Results and Provides Business Update

TORRANCE, Calif. , May 13, 2022 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today reporte...

1 year ago - PRNewsWire
}

Emmaus Life Sciences to Present at Investor Conferences in May

TORRANCE, Calif. , April  26, 2022  /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today ann...

1 year ago - PRNewsWire

Emmaus Life Sciences Presented Positive Real-World Data on the Efficacy of Endari® in Preventing Acute Complications from Sickle Cell Disease at the 62nd Annual Scientific Meeting of the British Society for Haematology

Sickle Cell Patients Treated With Endari ®  had Statistically Significantly Fewer Vaso-Occlusive Events and Hospitalizations Through 72 Weeks Follow-up, Versus Baseline Adverse Events Among These Pati...

1 year ago - PRNewsWire

Emmaus Life Sciences Reports 2021 Financial Results and Provides Business Update

TORRANCE, Calif. , March 31, 2022 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today repor...

1 year ago - PRNewsWire

Emmaus Life Sciences Announces Endari® To Be Added to the Florida Medicaid Preferred Drug List

Florida Joins Other States in Eliminating the Need for Prior Authorization for Medicaid Patients TORRANCE, Calif. , March 29, 2022 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX: EMMA), a leader in...

1 year ago - PRNewsWire

Emmaus Life Sciences Receives U.A.E. Marketing Authorization for Endari®

TORRANCE, Calif. , March 23, 2022 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX: EMMA) a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today announ...

1 year ago - PRNewsWire

Emmaus Life Sciences' Real World Data on Endari® Accepted for E-Poster at the 62nd Annual Scientific Meeting of the British Society for Haematology

TORRANCE, Calif., March 4, 2022 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today announc...

1 year ago - PRNewsWire

Insiders Buying These 3 Penny Stocks

Asian stock markets slumped on Tuesday amid escalating crisis in Russia and Ukraine. Investors, meanwhile, focused on some notable insider trades.

Other symbols: VIVK
1 year ago - Benzinga

Emmaus Life Sciences to Present at the H.C. Wainwright BioConnect Conference

TORRANCE, Calif., Jan. 4, 2022 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today announce...

1 year ago - PRNewsWire

Emmaus Life Sciences Presents Positive Transfusion Data from a Post-Hoc Analysis of its Phase 3 Clinical Study of Endari® in Patients With Sickle Cell Disease at the 63rd American Society of Hematology (ASH) Annual Meeting

TORRANCE, Calif., Dec. 14, 2021 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today announc...

1 year ago - PRNewsWire

Emmaus Life Sciences to Webcast Live at Life Sciences Investor Forum on December 16th

TORRANCE, Calif., Dec. 9, 2021 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today announce...

1 year ago - PRNewsWire

Emmaus Life Sciences' Data on Endari® Accepted for Poster Presentation at the 63rd American Society of Hematology Annual Meeting & Exhibition

TORRANCE Calif., Dec. 6, 2021 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today announced...

1 year ago - PRNewsWire

Emmaus Life Sciences Reports Third Quarter Financial Results and Business Highlights

TORRANCE, Calif., Nov. 12, 2021 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today reporte...

1 year ago - PRNewsWire